We note that HNSCC can promote Th2-skewed response by regulating IL-10 expression and secretion in the tumor microenvironment (Jewett et al., 2006; Young, 2006; Johnson et al., 2014) and that IL-10 has been shown to inhibit IFN-α production in HNSCC (Caruntu et al., 2022), which may lead to antitumor poor therapeutic efficacy. The gene discussed is IL10; the disease is head and neck squamous cell carcinoma.